Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation

NCT01280552 is registered in ClinicalTrials.gov with Precision Life Sciences Group as lead sponsor.

NCT NCT01280552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01280552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Lead sponsor
Precision Life Sciences Group
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2011
Completion date
December 31, 2015
Enrollment
124 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme